Reinventing the unsustainable pharmaceutical R&D model

Advancements in biotechnology are driving some of the most promising opportunities across all sections. There are two simple reasons for this. First, recent events have proven how vital and in-demand innovation is in this sphere. Second, venture funding and expenditure in this sector have grown 45% in only eight years. But despite this, many promising new treatments may never make it to market. The reason? The current R&D model for many pharmaceutical companies is unsustainable.

In our recent Capgemini publication, we look at the state of play in the pharmaceutical industry, highlighting challenges companies need to overcome not tomorrow but today. Rising costs, long cycle times, productivity and approval, and R&D process payors all need to be addressed. Our trilateral approach to reinventing the R&D model enables organizations to do exactly that.